ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Nearly half of patients with systemic sclerosis report symptoms of disordered eating, according to data published in Arthritis Care & Research.“We conducted this study to address a ...

Opinion Opinion: Systemic transportation underfunding requires new investment model Updated: Jul. 27, 2025, 7:11 a.m. | Published: Jul. 27, 2025, 7:00 a.m.

The global LUMUS Phase 2b trial is a randomized, double-blind, placebo-controlled study evaluating multiple doses of ESK-001 in adults with moderately-to-severely active, autoantibody-positive SLE.

NEW DELHI - Air India has been warned by India’s aviation regulator that it could face enforcement action for breaching safety standards related to crew fatigue management and training ...

[NEW DELHI] Air India has been warned by India’s aviation regulator that it could face enforcement action for breaching safety standards related to crew fatigue management and training, government ...

Air India has come under intense scrutiny since the Ahmedabad crash, which was the world's worst aviation disaster in a decade.

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus ...

NEW DELHI (Reuters) - Air India has been warned by India's aviation regulator that it could face enforcement action for breaching safety standards related to crew fatigue management and training ...

Systemic Lupus Erythematosus, also called Lupus, is an autoimmune condition where the body starts attacking its own cells. It can involve multiple systems like the skin, kidney, joints, etc.

Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of ESK-001 for the treatment of systemic ...

CHICAGO — In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has ...